Added to YB: 2026-01-02
Pitch date: 2025-12-07
SPRB [bullish]
Spruce Biosciences, Inc.
+5.38%
current return
Author Info
No bio for this author
Company Info
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders.
Market Cap
$93.2M
Pitch Price
$82.66
Price Target
222.00 (+169%)
Dividend
N/A
EV/EBITDA
-1.71
P/E
-1.06
EV/Sales
120.40
Sector
Biotechnology
Category
special_situation
Spruce Biosciences: Shkreli Pump or Value Stock?
SPRB: Biotech acquired TA-ERT for rare Sanfilippo B (~1/200k births). FDA granted breakthrough designation + confirmed CSF heparan sulfate as surrogate endpoint for accelerated approval. BLA filing Q1 2026, approval Q3-4 2026. ~110 US patients, $500k pricing = $90M peak sales. Plus $100M+ priority review voucher. Trading $104M mcap vs $230M+ fair value assuming 50%+ approval odds.
Read full article (8 min)